The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.
D. D. Von Hoff
Research Funding - Genentech
P. LoRusso
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
G. D. Demetri
Consultant or Advisory Role - EMD Serono; Genentech; GlaxoSmithKline; Kolltan Pharmaceuticals; Novartis; Pfizer; Plexxikon
Stock Ownership - Kolltan Pharmaceuticals; Plexxikon
Research Funding - Genentech; Novartis; Pfizer
G. J. Weiss
Research Funding - Genentech
G. Shapiro
Consultant or Advisory Role - Genentech
Research Funding - Genentech
R. K. Ramanathan
No relevant relationships to disclose
J. A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Roche
R. Raja
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. Jin
Employment or Leadership Position - Genentech
Stock Ownership - Roche
G. G. Levy
Employment or Leadership Position - Genentech
Stock Ownership - Roche
K. E. Mazina
Employment or Leadership Position - Genentech
Stock Ownership - Roche
A. J. Wagner
Consultant or Advisory Role - Genentech; Genentech; Infinity; Infinity; Novartis; Novartis
Honoraria - Novartis
Research Funding - Genentech